Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Heska Corporation HSKA NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score
53/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$159.50
+32.9%

Heska Corporation (HSKA) is a Medical - Devices company in the Healthcare sector, currently trading at $119.99. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is HSKA = $160 (+32.9% upside).

Financials: revenue is $257M, +30.3%/yr average growth. Net income is $18M (loss), growing at -5030.3%/yr. Net profit margin is -7.2% (negative). Gross margin is 43.2% (-1.2 pp trend).

Balance sheet: total debt is $103M against $422M equity (Debt-to-Equity (D/E) ratio 0.24, conservative). Current ratio is 6.7 (strong liquidity). Debt-to-assets is 17.6%. Total assets: $586M.

Analyst outlook: 8 / 16 analysts rate HSKA as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 67/100 (Partial), Moat 59/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).

$159.50
▲ 32.93% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Heska Corporation, the average price target is $159.50, with a high forecast of $170.00, and a low forecast of $149.00.
Highest Price Target
$170.00
Average Price Target
$159.50
Lowest Price Target
$149.00

HSKA SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 90/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 59/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HSKA

✓
VALUE Pass
90/100
HSKA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $160, implying +33.3% from the current price $120. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
HSKA: +30.3%/yr revenue is, -5030.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
HSKA: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet HSKA: Debt-to-Equity (D/E) ratio 0.24 (conservative), Current ratio is 6.7 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
59/100
HSKA: Gross margin is 43.2% (-1.2 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 59/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 8 / 16 analysts rate HSKA as buy (50%). Analyst consensus target is $160 (+33.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
HSKA: Net profit margin is -7.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range57.83-120.03
Volume330.89K
Avg Volume (30D)336.67K
Market Cap$1.31B
Beta (1Y)1.60
Dividend Yield$0.3000
Share Statistics
EPS (TTM)-1.78
Shares Outstanding$10.34M
IPO Date1997-07-01
Employees808
CEOKevin S. Wilson
Financial Highlights & Ratios
Revenue (TTM)$257.31M
Gross Profit$111.17M
EBITDA$-20.3M
Net Income$-18.42M
Operating Income$-20.3M
Total Cash$156.62M
Total Debt$103.07M
Net Debt$-53.55M
Total Assets$585.82M
Price / Earnings (P/E)-67.4
Price / Sales (P/S)5.09
Analyst Forecast
1Y Price Target$159.50
Target High$170.00
Target Low$149.00
Upside+32.9%
Rating ConsensusBuy
Analysts Covering16
Buy 50% Hold 50% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS42805E3062

Price Chart

Track all markets on TradingView
HSKA
Heska Corporation ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Devices
57.83 52WK RANGE 120.03

People Also View

GKOS
GKOS
Glaukos Corporation
$120.52
+0.86%
 BRKR
BRKR
Bruker Corporation
$39.90
+2.18%
 LIVN
LIVN
LivaNova PLC
$64.99
+0.63%
 ITGR
ITGR
Integer Holdings Corporation
$88.63
+1.03%
 NUVA
NUVA
NuVasive, Inc.
$39.75
-2.24%
 AORT
AORT
Artivion, Inc.
$37.95
-1.61%
 AXGN
AXGN
AxoGen, Inc.
$34.46
+2.96%
 CNMD
CNMD
CONMED Corporation
$39.73
+3.30%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message